ORKA Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (ORKA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 3% planned / 97% discretionary
Largest single sale: $300.0M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Goncalves Joana 4 fills | Chief Medical Officer | Sell 10b5-1 | 7,000 | $111.84 | $782.9K | 38,818 −15.3% of holding | |
| Quinlan Paul T 6 fills | General Counsel | Sell 10b5-1 | 52,000 | $108.49 | $5.6M | 79,404 −39.6% of holding | |
| Agarwal Arjun 5 fills | Senior Vice President, Finance | Sell 10b5-1 | 10,000 | $106.66 | $1.1M | 23,212 −30.1% of holding | |
| Goncalves Joana 4 fills | Chief Medical Officer | Sell 10b5-1 | 7,000 | $86.28 | $603.9K | 39,318 −15.1% of holding | |
| Agarwal Arjun 4 fills | Senior Vice President, Finance | Sell 10b5-1 | 9,999 | $84.63 | $846.2K | 25,011 −28.6% of holding | |
| Sell | 3,553,410 | $84.43 | $300.0M | 1,131,954 −75.8% of holding | |||
| Sandler Laura Lee 3 fills | Chief Operating Officer | Sell 10b5-1 | 5,000 | $94.42 | $472.1K | 239,147 −2% of holding | |
| Agarwal Arjun 2 fills | Senior Vice President, Finance | Sell 10b5-1 | 1,587 | $80.95 | $128.5K | 16,011 −9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.